QT Imaging to deliver Breast Acoustic CT scanner to research centers
QT Imaging Holdings is delivering its Breast Acoustic CT scanner in collaboration with research centers in the U.S. and Canada. The company is collaborating with the Department of Radiation Oncology and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, and the University of Illinois, Urbana-Champaign. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach that can accurately identify early response of breast cancer patients to neoadjuvant ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
Dr Mark Kris discusses neoadjuvant approaches for patients non-small cell lung cancer with oncogenic drivers for which there are effective targeted therapies.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news

In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
(MedPage Today) -- Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 28, 2024 Category: American Health Source Type: news

Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
FRIDAY, Feb. 23, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant benefit in terms of event-free survival (EFS), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2024 Category: Pharmaceuticals Source Type: news

Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC
(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news

Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer
Mark Kris, MD, discusses the use of a checkpoint inhibitor and chemotherapy as neoadjuvant therapy for every patient with stage II and III lung cancer at the time of diagnosis.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Pembrolizumab Improves Event-Free Survival in Early NSCLC
TUESDAY, Feb. 13, 2024 -- For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study presented at the annual meeting of The Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2024 Category: Pharmaceuticals Source Type: news

Neoadjuvant PD-1 Blockade Boosts pCR Rates in Early Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- Adding an investigational PD-1 inhibitor to chemotherapy in the neoadjuvant setting significantly improved pathological complete response (pCR) rates for patients with resectable locally advanced esophageal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 22, 2024 Category: Hematology Source Type: news

Standard Therapy Beats Out Primary Surgery in Rectal Cancer Standard Therapy Beats Out Primary Surgery in Rectal Cancer
In locally advanced rectal cancer, primary surgery followed by selective adjuvant chemoradiation was inferior to standard neoadjuvant preoperative chemoradiation followed by surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Multiparametric MRI helps predict breast cancer treatment outcomes
Multiparametric MRI helps predict breast cancer treatment response, according to a report on the RSNA's Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge published January 5 in Radiology: Imaging Cancer. The findings suggest that MRI could offer an effective way to tailor the care of women with the disease, wrote a team led by Wen Li, PhD, of the University of California, San Francisco. "Outcomes of the BMMR2 challenge provide further compelling evidence of the value of functional breast MRI as an early marker of treatment response that may aid in critical escalation and de-...
Source: AuntMinnie.com Headlines - January 8, 2024 Category: Radiology Authors: Kate Madden Yee Tags: MRI Womens Imaging Breast Imaging Source Type: news

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news

RSI predicts early response to chemotherapy in breast cancer
Restriction spectrum imaging (RSI) is a suitable method for evaluating neoadjuvant therapy response early for breast cancer, suggest findings presented December 6 at the San Antonio Breast Cancer Symposium. In her presentation, Maren Andreassen, MD, PhD, from the University of California, San Diego discussed her team’s work, which found that a novel RSI cancer tissue classifier predicted response to neoadjuvant therapy after three weeks. The team also found that RSI could identify most cases with residual tumor at surgery. “RSI performance was similar to performance by standard MRI by manual tumor measurement on dyna...
Source: AuntMinnie.com Headlines - December 8, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties MRI Breast Breast Imaging Source Type: news

Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer
(MedPage Today) -- SAN ANTONIO -- Adding an immune checkpoint inhibitor (ICI) to chemotherapy significantly increased the rate of pathologic complete response (pCR) and reduced residual cancer burden (RCB) in high-risk early-stage hormone receptor... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 7, 2023 Category: OBGYN Source Type: news